Thursday, 9 July 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 09 July 2026
News

Butler fires a delisting warning shot

Posted 9 July 2026 AM

Health Minister Mark Butler has fired a warning shot to two pharmas and the PBAC which are meeting to discuss two top PBS drugs for multiple sclerosis (MS) which are in danger of being delisted.

As public concern grows over the future funding of Roche's Ocrevus and Novartis' Kesimpta, Butler made it clear in a media conference yesterday that he is expecting both the PBAC and the pharma companies to do whatever it takes to ensure the drugs remain on the PBS.

To see the whole article, please login

Popular

Extra leave coming to pharma?
Another drug leaving Australia
J&J to pull drug worldwide
Red carpet win for cheeky campaign
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Access & Reimbursement (1)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home